Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Shares Outstanding (Weighted Average) (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $34.8 million for Q2 2025.

  • For Q2 2025, Shares Outstanding (Weighted Average) rose 14.26% year-over-year to $34.8 million; the TTM value through May 2025 reached $34.8 million, up 14.26%, while the annual FY2025 figure was $34.8 million, 14.26% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q2 2025 was $34.8 million at Lifecore Biomedical, Inc. \De\, down from $37.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $37.0 million in Q1 2025 and troughed at $29.3 million in Q2 2021.
  • A 5-year average of $30.8 million and a median of $30.1 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 0.45% in 2021 and later grew 21.58% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $29.5 million in 2021, then increased by 0.55% to $29.6 million in 2022, then rose by 2.69% to $30.4 million in 2023, then increased by 12.91% to $34.4 million in 2024, then rose by 1.33% to $34.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for LFCR at $34.8 million in Q2 2025, $37.0 million in Q1 2025, and $34.4 million in Q4 2024.